CYTOKINETICS INC — fact timeline

CYTOKINETICS INC reported first quarter of 2026 results: revenue $19.4 million.

“Cash, cash equivalents and investments declined by approximately $144 million during the first quarter of 2026. Revenues • Total revenues for the first quarter of 2026 were $19.4 million, compared to $1.6 million for the same period in 2025. Total revenues in the first quarter of 2026 include: o $4.8 million MYQORZO net product revenue which represents”

CYTOKINETICS INC incurred convertible notes of $750.0 million aggregate principal amount with initial purchasers at 1.75% per year maturing October 1, 2031.

“On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.”

Robert E. Landry was appointed as Director at CYTOKINETICS INC.

“On February 10, 2025, (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Cytokinetics, Incorporated (the “ Company ”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, Robert E. Landry to fill a vacant Board seat and to serve as a Class II member of the Board with an initial term expiring at the Company’s 2027 annual meeting of stockholders.”

Santo J. Costa resigned as Director at CYTOKINETICS INC.

“On November 1, 2024, Santo J. Costa notified Cytokinetics, Incorporated (the "Company") of his resignation from the Board of Directors of the Company (the "Board of Directors"), with immediate effect.”

Brett Pletcher was appointed as Executive Vice President, Chief Legal Officer at CYTOKINETICS INC.

“On August 13, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Brett Pletcher, pursuant to which Mr. Pletcher has agreed to serve as the Company’s Executive Vice President, Chief Legal Officer, effective as of August 19, 2024 (the “Start Date”).”

CYTOKINETICS INC shareholders approved Advisory Vote on Executive Compensation.

“Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the 2024 Proxy Statement. The votes were as follows: For Against Abstain Broker Non-Vote 85,814,395 2,927,007 790,693 6,649,555”

CYTOKINETICS INC shareholders approved Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-12-31 meeting.

“Proposal 3: Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 The stockholders ratified the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were as follows: For Against Abstain 95,957,265 97,750 126,635”

CYTOKINETICS INC shareholders approved Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock..

“Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The stockholders approved the Amendment and Restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of shares authorized for issuance under such plan by 300,000 shares of common stock. The votes were as follows: For Against Abstain Broker Non-Vote 88,586,473 481,098 464,524 6,649,555”

CYTOKINETICS INC shareholders approved Election of Two Class II Directors.

“Proposal 1: Election of Two Class II Directors The stockholders elected Robert I. Blum and Robert A. Harrington, M.D. as Class II Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows: Name For Withheld Broker Robert I. Blum 87,317,169 2,214,926 6,649,555 Robert A. Harrington, M.D. 78,347,186 11,184,909 6,649,555”

Sandford D. Smith resigned as Director at CYTOKINETICS INC.

“On May 15, 2024, Sandford D. Smith notified Cytokinetics, Incorporated (the “Company”) of his resignation from the Board of Directors of the Company (the “Board of Directors”), with such resignation effective immediately before the 2024 annual meeting of stockholders of the Company held on May 15, 2024 (the “Annual Meeting”).”